Diabetes mellitus and prognosis after curative therapy for hepatocellular carcinoma: Alas, still grave for those who are hyperglycemic

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 11, 2008, Pages 1633-1634

  Teoh, Narci C ^a,c   Fan, Jian Gao ^b  

^a Canberra Hospital   (Australia)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^c CANBERRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA FETOPROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SOMATOMEDIN;

ADIPOCYTE; ALCOHOL CONSUMPTION; CANCER SURVIVAL; CHRONIC HEPATITIS; DIABETES MELLITUS; DISEASE ASSOCIATION; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IN VIVO CULTURE; LIVER CELL CARCINOMA; MASCULINITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; RISK FACTOR; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; VIRUS INFECTION;

EID: 56549120156     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05648.x     Document Type: Editorial

References (21)

1. Harrison SA. Liver disease in patients with diabetes mellitus. J. Clin. Gastroenterol. 2006 40 : 68 76.
2. El-Serag HB, Hampel H, JAvadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 2006 4 : 369 80.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 : 2557 76.
4. Ikeda Y, Shimada M, Hasegawa H et al. Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 1998 27 : 1567 71.
5. Lai MS, Hsieh MS, Chiu YH, Chen THH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006 43 : 1295 302.
6. Poon RTP, Fan ST, Wong J. Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? Am. J. Gastroenterol. 2002 97 : 1480 8.
7. Komura T, Mizukoshi E, Kita Y et al. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am. J. Gastroenterol. 2007 102 : 1939 46.
8. Huo TI, Wu JC, Lui WY et al. Diabetes mellitus is a recurrence- independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. Eur. J. Gastroenterol. Hepatol. 2003 15 : 1203 8.
9. Toyoda H, Kumada T, Nakano S et al. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. Cancer 2001 91 : 957 63.
10. Huo TI, Wu JC, Lui WY et al. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am. J. Gastroenterol. 2004 99 : 1479 87.
11. Kawamura Y, Ikeda K, Arase Y et al. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with non-viral hepatitis. J. Gastroenterol. Hepatol. 2008 23 : 1733 40.
12. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002 35 : 373 9.
13. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006 43 : S99 112.
14. Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr. Mol. Med. 2003 3 : 561 72.
15. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology 2007 132 : 2208 25.
16. Alexia C, Fallot G, Lasfer M et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signaling in heaptocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem. Pharmacol. 2004 68 : 1003 15.
17. Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome and breast cancer in African-American and White American Women. Endocr. Rev. 2007 28 : 763 77.
18. Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabetes Metab. 1992 18 : 187 201.
19. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 2004 68 : 975 81.
20. Mantzoros C, Petridou E, Dessypris N et al. Adiponectin and breast cancer risk. J. Clin. Endocrinol. Metab. 2004 89 : 1102 7.
21. Brakenhielm E, Veitonmaki N, Cao R et al. Adiponectin-induced anti-angiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl. Acad. Sci. 2004 101 : 2476 81.